scholarly journals Correction: Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0191508
Author(s):  
Andreas Austgulen Westin ◽  
Malin Brekke ◽  
Espen Molden ◽  
Eirik Skogvoll ◽  
Olav Spigset
PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181082 ◽  
Author(s):  
Andreas Austgulen Westin ◽  
Malin Brekke ◽  
Espen Molden ◽  
Eirik Skogvoll ◽  
Olav Spigset

2010 ◽  
Vol 41 (1) ◽  
pp. 15-17 ◽  
Author(s):  
C. M. Pariante ◽  
G. Seneviratne ◽  
L. Howard

A new Swedish study by Reis & Källén describes approximately 15 000 women (and their babies) that, between 1995 and 2007, reported the use of antidepressants, or were prescribed such drugs, during pregnancy. In this study, pregnancy and teratogenic outcomes after exposure to tricyclic antidepressants are, for most measures, equal or worse than after exposure to selective serotonin reuptake inhibitors or other antidepressants. Based on this and on a review of the few other studies available (admittedly, a relatively small number of women on which conclusions can be based), the authors of this Editorial challenge the ‘perinatal myth’ that tricyclics are the safest choice in pregnancy.


2013 ◽  
Vol 6 (4) ◽  
pp. 155-158 ◽  
Author(s):  
Zbigniew Marchocki ◽  
Noirin E Russell ◽  
Keelin O’ Donoghue

Depression is common in women of childbearing age. Whereas non-pharmacological interventions are recommended as first line interventions, pharmacological treatment may be required. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants in pregnancy. Ideally, discussion of the risks and benefits of SSRI use in pregnancy should occur prior to pregnancy. The potential risks of psychotropic medications need to be balanced against the risks associated with untreated psychiatric conditions and the discontinuation of necessary medications.


Sign in / Sign up

Export Citation Format

Share Document